Zydus Lifesciences has agreed to pay Astellas Pharma $120 million to settle a U.S. patent lawsuit over mirabegron, a generic drug for bladder problems. Picture credit score: Reuters
Zydus Lifesciences has agreed to pay Astellas Pharma $120 million to settle a U.S. patent lawsuit over mirabegron, a generic drug for bladder problems.
Based on Zydus, the corporate and its subsidiary Zydus Prescribed drugs USA, Inc. have entered right into a settlement settlement concerning Astellas and RELIATION’s Miratric (generic title: mirabegron).
Below the settlement, Zydus pays Astellas a complete of $120 million. As well as, from the date of the settlement settlement till September 2027, Zydus pays an upfront license price for every unit of generic mirabegron bought in the USA. Different phrases of the settlement stay confidential, Zydas mentioned.
The settlement ends all litigation between Astellas and the businesses concerning milvetrique and mirabegron, and Zydus mentioned it may well proceed to promote the generic drug mirabegron in the USA.
In April 2025, the USA District Court docket for the District of Delaware issued an order in favor of the inventor in a lawsuit introduced by Astellas towards Zydus concerning the validity of a U.S. patent. Patent infringement, damages and different invalidity claims shall be litigated in a consolidated jury trial in 2026, Zydus mentioned in a submitting on the time.
Earlier this week, one other Indian generic drug maker, Lupine, introduced it had entered right into a settlement and license settlement with Astellas Pharma to resolve pending litigation. Below the settlement, Lupine pays Astellas $90 million and proceed to promote mirabegron.
